Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24828312 | 0.77 | CSF1R (0.35) | CRHR1KMT2A | |
| SCHEMBL30190161 | 0.75 | CRHR1 (0.37) | CRHR1ALPLALPIALPGKMT2A | |
| SCHEMBL24828232 | 0.74 | CRHR1 (0.37) | CRHR1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL14550285 | 0.73 | L3MBTL1 (0.41) | CRHR1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL24828231 | 0.71 | SMN1; SMN2 (0.37) | CRHR1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL24007251 | 0.71 | CRHR1 (0.36) | CRHR1KMT2APOLBLMNALRRK2 | |
| SCHEMBL24828656 | 0.70 | LMNA (0.32) | CRHR1LMNA | |
| SCHEMBL25108519 | 0.68 | KMT2A (0.33) | CRHR1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL24828521 | 0.68 | CRHR1 (0.30) | CRHR1 | |
| SCHEMBL24828390 | 0.68 | LRRK2 (0.35) | CRHR1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542278-B1 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, CYP3A43 | CRHR1 2547/4885ALPL 2719/4885ALPI 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.